Supreme Court to Weigh Liability of Generic Drug Makers for 'Skinny Label' Patent Infringement in Hikma v. Amarin

Supreme Court to Weigh Liability of Generic Drug Makers for 'Skinny Label' Patent Infringement in Hikma v. Amarin On January 16, 2026, the U.S. Supreme Court granted certiorari to review a Federal Circuit ruling in Hikma Pharmaceuticals USA v. Amarin Pharma. The case centers on whether generic drug makers who exclude patented uses... Read the full IIPLA article: https://iipla.org/news/supreme-court-to-weigh-liability-of-generic-drug-makers-for-skinny-label-patent-infringement-in-hikma-v-amarin